Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome
About
Immune-mediated, non-communicable diseases, such as autoimmune diseases, allergic diseases and asthma, are chronic disorders in which the immune system plays a pivotal role. The World Health Organisation (WHO) has highlighted the seriousness of autoimmunity and its association with exposure to the environment.
EXIMIOUS aims to deliver a new way of assessing the human exposome, i.e. the exposures to environmental factors that one experiences throughout life, and shed light on its association to immune-mediated diseases.
Partners
EXIMIOUS is part of the European Human Exposome Network and brings together 15 partner organisations from 7 European countries.
Latest Tweets
Latest news
‘Do chemicals penetrate human skin?’ – Take-aways from the 4th EXIMIOUS Symposium
More than 80 participants joined the fourth EXIMIOUS Symposium. Did you miss it? Read about it here and watch the full recording.
Registration is open for the 4th EXIMIOUS Symposium
Join us online on 26 January 2023 at 16:00 – 18:00 CET for the EXIMIOUS Symposium “Do chemicals penetrate human skin? How skin absorption of chemicals contributes to human exposure”.
EHEN’s November 2022 Newsletter – focus on the health impact of exposome research
The European Human Exposome Network (EHEN) third newsletter announces the launch of its Toolbox and introduces the health impact of exposome reaserach and the diseases studied by the nine EHEN projects, including EXIMIOUS.
Project facts
EXIMIOUS is a 5 year Research and Innovation Action funded by the European Union’s Horizon 2020 programme.
- Concept: introduce a new approach to mapping exposure-induced immune effects by combining exposomics and immunomics in a unique toolbox.
- Budget: 10.8 million Euro
- Duration: 01.01.2020 - 31.12.2024
FAQ
Don’t know what the exposome is?
Want to know more about exposure-related immune diseases?
Curious to know more about what to expect from this project?
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874707.
